Immunosuppression News and Research

RSS

Immunosuppression involves an act that reduces the activation or efficacy of the immune system. Some portions of the immune system itself have immuno-suppressive effects on other parts of the immune system, and immunosuppression may occur as an adverse reaction to treatment of other conditions.

Study reveals subtypes and EBV-associated regulatory epigenome reprogramming in nasopharyngeal carcinoma

Researchers from the Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong (HKUMed) discovered a novel subtype of Epstein-Barr Virus (EBV)-positive nasopharyngeal carcinoma (NPC) and EBV-associated immunosuppression in the tumor microenvironment (TME).

16 Dec 2022

The effectiveness of nirmatrelvir-ritonavir and molnupiravir for the treatment of COVID-19 among US veterans

Researchers evaluated the effectiveness of SARS-CoV-2 antivirals, nirmatrelvir-ritonavir, and molnupiravir among Veterans in the United States of America.

13 Dec 2022

Review: Phenotypes and origins of myeloid-derived suppressor cells

A new review was published in Oncotarget's Volume 13 on November 17, 2022, entitled, "Myeloid-derived suppressor cells: Cancer, autoimmune diseases, and more."

30 Nov 2022

Novel cancer-fighting nanoparticles co-deliver a chemotherapy drug and immunotherapy

University of Pittsburgh researchers have designed cancer-fighting nanoparticles that co-deliver a chemotherapy drug and a novel immunotherapy, according to a new Nature Nanotechnology study published today.

24 Nov 2022

Long-term humoral response and its determinants following 2- and 3-dose COVID-19 mRNA vaccines

Researchers compared the waning of vaccine-induced immunity from two and three doses of mRNA COVID-19 Pfizer-BioNTech vaccine BNT162b2 by conducting a repeated serological study to assess the prolonged humoral response.

14 Nov 2022

Study: No significant difference in cancer risk in rheumatology patients with history of malignancy taking DMARDs

New research presented this week at ACR Convergence 2022, the American College of Rheumatology's annual meeting, found no significant difference in cancer risk in patients with rheumatic disease and a history of malignancy taking biologic or targeted synthetic DMARDs compared to those treated with TNF inhibitors.

8 Nov 2022

Combining chemotherapy with an inflammation inhibitor can prevent breast cancer metastasis

A new treatment developed at Tel Aviv University may significantly enhance the efficacy of chemotherapy in breast cancer patients, reducing the risk for lung metastasis following chemo from 52% to only 6%.

7 Nov 2022

Shared genetic effects between the autoimmune disease systemic lupus erythematosus and the clinical consequences of COVID-19

Researchers identified a genetic association signal, via genome-wide association studies, between severe COVID-19 with systemic lupus erythematosus, an autoimmune disease.

7 Nov 2022

The long-term impact of COVID-19 severity on health-related quality of life

A recent study conducted on the residents of Amsterdam, the Netherlands, describes that people with mild COVID-19 experience better health-related quality of life after one year of disease onset than those with moderate or severe COVID-19.

3 Nov 2022

Researchers find the root of immunosuppression and chemoresistance in TNBC tumors

Triple-negative breast cancer (TNBC) tumors gain immunosuppression and chemoresistance through interactions between interleukin 34 and myeloid-derived suppressor cells, researchers find.

1 Nov 2022

What are the implications of microbial ecosystems for female reproductive health?

Researchers reviewed the current understanding of the composition and temporal dynamics of microbial niches in the female reproductive tract.

31 Oct 2022

Updated EULAR recommendations for children with pedAIIRD

People with autoimmune or auto-inflammatory rheumatic diseases have an increased risk of infections. This can be due to the underlying disease itself, or may be caused by treatment with immunomodulating or immunosuppressive drugs.

28 Oct 2022

Is vaccine status associated with the severity of Omicron SARS-CoV-2 infection in hospitalized patients?

Researchers assessed the impact of SARS-CoV-2 vaccination on the occurrence and severity of symptoms in SARS-CoV-2 Omicron-infected hospitalized patients.

27 Oct 2022

FebriDX point-of-care immunoassay can rapidly determine if an infection is bacterial or viral

Researchers explore whether FebriDx could differentiate between bacteria- and virus-induced immune responses during acute respiratory infection.

23 Oct 2022

Review of characteristics of human monkeypox

Researchers conducted a scoping review of available literature on monkeypox (MPX), in a new study.

20 Oct 2022

Livers have a cumulative age of at least 100 years, researchers find

There is a small, but growing, subset of livers that have been transplanted and have a cumulative age of more than 100 years, according to researchers from University of Texas (UT) Southwestern Medical Center, Dallas, and TransMedics, Andover, Massachusetts.

17 Oct 2022

UNO-peptide-modified CCN shows promise for targeted delivery of TAM immunomodulatory agents

Announcing a new publication for Acta Materia Medica journal. Tumor-associated macrophages (TAMs) are key contributors to tumor development, accelerated tumor invasion and metastasis, and induction of immunosuppression.

13 Oct 2022

Multiomic comparison shows a reduction in circulating monocytes correlated with persistent post-COVID-19 pulmonary fibrosis

In a new study, researchers identified distinguishing immune features of coronavirus disease 2019 (COVID-19) in patients with late-resolving pulmonary fibrosis (LR COVID-PF) and early-resolving (ER COVID-PF).

4 Oct 2022

Exploring remdesivir resistance in COVID-19-infected transplant recipients

In a new study, researchers assessed the remdesivir resistance developed in coronavirus disease 2019 (COVID-19)-infected transplant recipients.

29 Sep 2022

Debunking ‘man flu’

Researchers debunk man flu based on a review of available evidence.

28 Sep 2022